Literature DB >> 22166428

Genetic mouse models for understanding LRRK2 biology, pathology and pre-clinical application.

Zhenyu Yue1.   

Abstract

Missense mutations in Leucine-Rich Repeat kinase 2 (LRRK2) are the most common cause of inherited Parkinson's disease (PD). Elucidation of LRRK2 biology and pathophysiology is central to the development of therapeutic intervention. Our group and others have developed a number of genetic mouse models of LRRK2 utilizing different genetic approaches. These models exhibit certain PD-related pathologies (e.g. impaired dopamine transmission and tauopathies) and abnormal motor functions, providing valuable insight into potential LRRK2-mediated pathogenesis of PD. However, not surprisingly they lack of substantial neuropathology and clinical syndromes of PD. Ongoing investigation of these models has begun to shed light on LRRK2 cellular functions and pathogenic pathways and is expected to assist the identification and validation of PD drug targets. This report summarizes the recent findings in our genetic LRRK2 models and discusses their utility in understanding much needed knowledge regarding early stage (pre-symptomatic) disease progression, drug target identification, and potential application in chemical screening focused on inhibitors of kinase activity of LRRK2.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22166428      PMCID: PMC3972057          DOI: 10.1016/S1353-8020(11)70056-6

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  20 in total

Review 1.  BAC to the future: the use of bac transgenic mice for neuroscience research.

Authors:  N Heintz
Journal:  Nat Rev Neurosci       Date:  2001-12       Impact factor: 34.870

2.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity.

Authors:  Andrew B West; Darren J Moore; Catherine Choi; Shaida A Andrabi; Xiaojie Li; Dustin Dikeman; Saskia Biskup; Zhenshui Zhang; Kah-Leong Lim; Valina L Dawson; Ted M Dawson
Journal:  Hum Mol Genet       Date:  2007-01-02       Impact factor: 6.150

3.  Parkinsonism, Lrrk2 G2019S, and tau neuropathology.

Authors:  A Rajput; D W Dickson; C A Robinson; O A Ross; J C Dächsel; S J Lincoln; S A Cobb; M L Rajput; M J Farrer
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

4.  Kinase activity of mutant LRRK2 mediates neuronal toxicity.

Authors:  Wanli W Smith; Zhong Pei; Haibing Jiang; Valina L Dawson; Ted M Dawson; Christopher A Ross
Journal:  Nat Neurosci       Date:  2006-09-17       Impact factor: 24.884

5.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease.

Authors:  Genta Ito; Takuro Okai; Go Fujino; Kohsuke Takeda; Hidenori Ichijo; Toshiaki Katada; Takeshi Iwatsubo
Journal:  Biochemistry       Date:  2007-02-06       Impact factor: 3.162

6.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity.

Authors:  Andrew B West; Darren J Moore; Saskia Biskup; Artem Bugayenko; Wanli W Smith; Christopher A Ross; Valina L Dawson; Ted M Dawson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-03       Impact factor: 11.205

7.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology.

Authors:  Z K Wszolek; R F Pfeiffer; Y Tsuboi; R J Uitti; R D McComb; A J Stoessl; A J Strongosky; A Zimprich; B Müller-Myhsok; M J Farrer; T Gasser; D B Calne; D W Dickson
Journal:  Neurology       Date:  2004-05-11       Impact factor: 9.910

8.  Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology.

Authors:  Alexander Zimprich; Saskia Biskup; Petra Leitner; Peter Lichtner; Matthew Farrer; Sarah Lincoln; Jennifer Kachergus; Mary Hulihan; Ryan J Uitti; Donald B Calne; A Jon Stoessl; Ronald F Pfeiffer; Nadja Patenge; Iria Carballo Carbajal; Peter Vieregge; Friedrich Asmus; Bertram Müller-Myhsok; Dennis W Dickson; Thomas Meitinger; Tim M Strom; Zbigniew K Wszolek; Thomas Gasser
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

9.  Neurocirculatory and nigrostriatal abnormalities in Parkinson disease from LRRK2 mutation.

Authors:  D S Goldstein; R Imrich; E Peckham; C Holmes; G Lopez; C Crews; J Hardy; A Singleton; M Hallett
Journal:  Neurology       Date:  2007-07-11       Impact factor: 9.910

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  7 in total

1.  Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.

Authors:  Guoxiang Liu; Carmelo Sgobio; Xinglong Gu; Lixin Sun; Xian Lin; Jia Yu; Loukia Parisiadou; Chengsong Xie; Namratha Sastry; Jinhui Ding; Kelly M Lohr; Gary W Miller; Yolanda Mateo; David M Lovinger; Huaibin Cai
Journal:  Hum Mol Genet       Date:  2015-06-29       Impact factor: 6.150

2.  LRRKing up the right trees? On figuring out the effects of mutant LRRK2 and other Parkinson's disease-related genes.

Authors:  Heinz Steiner
Journal:  Basal Ganglia       Date:  2013-07-01

Review 3.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

Review 4.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

Review 5.  Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models.

Authors:  Thomas Kramer; Fabio Lo Monte; Stefan Göring; Ghislaine Marlyse Okala Amombo; Boris Schmidt
Journal:  ACS Chem Neurosci       Date:  2012-01-18       Impact factor: 4.418

6.  VPS35 D620N knockin mice recapitulate cardinal features of Parkinson's disease.

Authors:  Mengyue Niu; Fanpeng Zhao; Karina Bondelid; Sandra L Siedlak; Sandy Torres; Hisashi Fujioka; Wenzhang Wang; Jun Liu; Xiongwei Zhu
Journal:  Aging Cell       Date:  2021-03-21       Impact factor: 9.304

7.  Comprehensive characterization and optimization of anti-LRRK2 (leucine-rich repeat kinase 2) monoclonal antibodies.

Authors:  Paul Davies; Kelly M Hinkle; Nour N Sukar; Bryan Sepulveda; Roxana Mesias; Geidy Serrano; Dario R Alessi; Thomas G Beach; Deanna L Benson; Charles L White; Rita M Cowell; Sonal S Das; Andrew B West; Heather L Melrose
Journal:  Biochem J       Date:  2013-07-01       Impact factor: 3.857

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.